{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/prescribing-information/beta-blockers/","result":{"pageContext":{"chapter":{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers","depth":2,"htmlHeader":"<!-- begin field 37d456bf-52bd-4ced-bbe5-d044a8ae4fa1 --><h2>Beta-blockers</h2><!-- end field 37d456bf-52bd-4ced-bbe5-d044a8ae4fa1 -->","summary":"","htmlStringContent":"<!-- begin item 5217f9cc-796c-4e04-9261-c1968b03e49f --><!-- end item 5217f9cc-796c-4e04-9261-c1968b03e49f -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"a0639553-aa3d-550b-ac6b-488b10d2f4a8","slug":"choice-of-beta-blocker","fullItemName":"Choice of beta-blocker","depth":3,"htmlHeader":"<!-- begin field 950ca0c1-9dbf-41a7-978e-40cdc74b9654 --><h3>Choice of beta-blocker</h3><!-- end field 950ca0c1-9dbf-41a7-978e-40cdc74b9654 -->","summary":"","htmlStringContent":"<!-- begin item f779f5da-ca66-4a0e-922d-d547570db987 --><!-- begin field be15b88a-0f12-4c78-ae7c-6a463eac0137 --><ul><li>The following beta-blockers are licensed for the treatment of angina: propranolol, acebutolol, atenolol, bisoprolol, carvedilol, metoprolol, nadolol, oxprenolol, pindolol, and timolol.</li><li>For people who have had a previous myocardial infarction, metoprolol (standard release), propranolol (standard release), timolol, or atenolol may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>.</li></ul></li><li>For people with angina and heart failure, bisoprolol, carvedilol, or nebivolol may be preferred.<ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>.</li></ul></li></ul><p>These recommendations are based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of stable angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">SIGN, 2007</a>], the European Society of Cardiology (ESC) guideline <em>Management of stable coronary artery disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ESC, 2013</a>], and the British National Formulary (BNF) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]. </p><ul><li>There is no good evidence that any one beta-blocker is better than any other in the management of stable angina. The efficacy of beta-blockers is thought to be due to a class effect rather than the effects of individual drugs, and such factors as comorbidity, compliance, and cost should be considered when selecting a beta-blocker. Occasionally, an individual may respond better to one beta-blocker than another [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">SIGN, 2007</a>].</li><li>Atenolol, bisoprolol, and metoprolol are cardioselective and do not exhibit intrinsic sympathomimetic activity [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>].</li></ul><!-- end field be15b88a-0f12-4c78-ae7c-6a463eac0137 --><!-- end item f779f5da-ca66-4a0e-922d-d547570db987 -->","subChapters":[]},{"id":"1e022441-eeef-53ea-bc21-9b1cb16ce233","slug":"dose-titration","fullItemName":"Dose and titration","depth":3,"htmlHeader":"<!-- begin field 20a1995c-d196-4a2c-9f34-59b3af906f21 --><h3>Dose and titration</h3><!-- end field 20a1995c-d196-4a2c-9f34-59b3af906f21 -->","summary":"","htmlStringContent":"<!-- begin item 7ce49d82-e0b9-47af-9375-1de9e19fa1a3 --><!-- begin field 709e3a7a-bd80-4266-8915-e7f4c86e092b --><ul><li>Titrate the dose of beta-blocker to the target dose (or maximum tolerated dose), according to the person's response and heart rate control (at rest and during exercise).</li><li>Recommended doses are:<ul><li>Atenolol 100 mg once a day or 50 mg twice a day (twice-daily dosing may provide better symptom control).</li><li>Bisoprolol 5–10 mg once a day.</li><li>Metoprolol 50–100 mg two to three times a day (standard-release) or 200–400 mg once a day (modified-release).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">SIGN, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field 709e3a7a-bd80-4266-8915-e7f4c86e092b --><!-- end item 7ce49d82-e0b9-47af-9375-1de9e19fa1a3 -->","subChapters":[]},{"id":"35b41437-47d7-540d-bc47-d3708c19baf5","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field aa77cd11-961f-4151-9ed6-6f192b396eab --><h3>Adverse effects</h3><!-- end field aa77cd11-961f-4151-9ed6-6f192b396eab -->","summary":"","htmlStringContent":"<!-- begin item 9d24d034-05eb-4d2c-855e-b91d11367486 --><!-- begin field 3d64c300-34fe-4d30-b85f-e31d0afda1d4 --><ul><li><strong>Adverse effects of beta-blockers include:</strong><ul><li>Deteriorating symptoms of heart failure (such as symptoms of fluid overload and fatigue).</li><li>Hypotension.</li><li>Bradycardia.</li><li>Dizziness, headache, and syncope.</li><li>Nausea, vomiting, diarrhoea, and constipation.</li><li>Sexual dysfunction — including erectile dysfunction and loss of libido.</li><li>Cold extremities, paraesthesia, and numbness — these are more common in people with peripheral arterial disease. If these are troublesome, the beta-blocker may need to be stopped.</li><li>Effect on carbohydrate metabolism — hypo- or hyperglycaemia in people with or without diabetes mellitus.</li><li>Effect on metabolic and autonomic response to hypoglycaemia — possible masking of hypoglycaemia warning signs such as tremor and tachycardia.</li><li>Fatigue and asthenia (lack of energy and strength) — is a common adverse effect of bisoprolol.</li><li>Sleep disturbance, nightmares, and depression.</li><li>Bronchospasm.</li><li>Reduction of secretion of lacrimal fluid (may affect people who wear contact lenses).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016l</a>]</p><!-- end field 3d64c300-34fe-4d30-b85f-e31d0afda1d4 --><!-- end item 9d24d034-05eb-4d2c-855e-b91d11367486 -->","subChapters":[]},{"id":"590c8d40-4c95-59d9-b221-a67c02370846","slug":"cautions-contraindications","fullItemName":"Cautions and contraindications","depth":3,"htmlHeader":"<!-- begin field e41f45c0-6d9a-49de-b6c4-2a28b84d1c0a --><h3>Cautions and contraindications</h3><!-- end field e41f45c0-6d9a-49de-b6c4-2a28b84d1c0a -->","summary":"","htmlStringContent":"<!-- begin item b9ffbab9-3912-4e52-ba7e-b87437f321e3 --><!-- begin field 82cdbf57-00d1-413a-a2e9-0e89046b45dd --><ul><li><strong>Do not prescribe beta-blockers to people with:</strong><ul><li>A history of asthma or bronchospasm.</li><li>Reversible or severe chronic obstructive pulmonary disease (COPD). Beta-blockers can be used in people with COPD without significant reversible airways obstruction.</li><li>Known intolerance or hypersensitivity to beta-blockers.</li><li>Severe or symptomatic bradycardia (heart rate less than 60 beats per minute).</li><li>Sinoatrial block, second- or third-degree heart block (unless there is a pacemaker in place).</li><li>Severe or uncontrolled heart failure.</li><li>Severe or symptomatic hypotension (systolic blood pressure less than 90 mmHg).</li><li>Severe peripheral arterial disease (including intermittent claudication) or Raynaud's syndrome.</li><li>Sick sinus syndrome.</li><li>Cardiogenic shock or phaeochromocytoma (without a concomitant alpha-blocker).</li><li>People with frequent episodes of hypoglycaemia.</li><li>Clinically significant hepatic dysfunction (carvedilol and nebivolol).</li><li>Some beta-blocker preparations contain lactulose and should not be used by people with rare hereditary problems of galactose intolerance, fructose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.</li></ul></li><li><strong>Prescribe beta-blockers with caution to people with:</strong><ul><li>Heart failure with chronic kidney disease (CKD), hypotension, ischaemic heart disease, or less severe peripheral arterial disease.</li><li>Prinzmetal's angina.</li><li>Current or recent (within 4 weeks) exacerbation of heart failure - seek specialist advice.</li><li>First-degree atrioventricular heart block.</li><li>Portal hypertension (risk of deterioration in liver function).</li><li>Diabetes mellitus (effects carbohydrate metabolism and symptoms of hypoglycaemia may be masked).</li><li>COPD.</li><li>Mysthenia gravis.</li><li>Psoriasis.</li><li>Thyrotoxicosis (symptoms may be masked).</li><li>People who wear contact lenses (reduced secretion of lacrimal fluid).</li><li>History of hypersensitivity to allergens - beta-blockers may increase sensitivity to allergens and result in a more serious hypersensitivity response, and may reduce response to adrenaline (epinephrine).</li><li>CKD.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field 82cdbf57-00d1-413a-a2e9-0e89046b45dd --><!-- end item b9ffbab9-3912-4e52-ba7e-b87437f321e3 -->","subChapters":[]},{"id":"6e855a64-6d4a-5f69-9d79-50fd4f6e5534","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 87d41b50-f1aa-4fea-b6f5-273ee59209ba --><h3>Drug interactions</h3><!-- end field 87d41b50-f1aa-4fea-b6f5-273ee59209ba -->","summary":"","htmlStringContent":"<!-- begin item 7ca7aadd-5f19-4cda-b721-3444617b1368 --><!-- begin field 3d88d349-12cf-4017-a43e-d5076aa38935 --><p><strong>Important drug interactions of beta-blockers include:</strong></p><ul><li><strong>Antipsychotics and antidepressants</strong> (tricyclic, barbiturates, and phenothiazines) — risk of hypotension.</li><li><strong>Baclofen</strong> — prescribe with caution due to increased hypotensive effect.</li><li><strong>Dihydropyridine calcium-channel blockers</strong> (including amlodipine, felodipine, and nifedipine) — risk of increased hypotension and worsening heart failure.</li><li><strong>Verapamil</strong> — concurrent beta-blocker and verapamil should not be prescribed because of the risk of bradycardia, asystole, severe hypotension, and heart failure.</li><li><strong>Diltiazem</strong> — obtain specialist advice before prescribing diltiazem with a beta-blocker.<ul><li>Heart rate and blood pressure should be monitored carefully, as bradycardia and atrioventricular (AV) block can occur. Asystole and sudden death have been reported.</li></ul></li><li><strong>Class I antiarrhythmics</strong> (such as quinidine, flecainide) — concurrent treatment should be avoided due to bradycardia, myocardial depression and potentiation of AV conduction time.</li><li><strong>Class III antiarrhythmics</strong> (such as amiodarone) — concurrent treatment should be prescribed with caution.<ul><li>Monitor heart rate and blood pressure and check for signs of worsening heart failure, as risk of bradycardia, AV block, and myocardial depression is increased.</li></ul></li><li><strong>Digoxin</strong> — concurrent treatment can reduce heart rate and prolong AV conduction time, increasing the risk of AV block and bradycardia.<ul><li>Monitor pulse carefully.</li><li>Monitor for signs of digoxin toxicity with carvedilol (confusion, anorexia, nausea, disturbance of colour vision) as an increase in plasma digoxin levels has been reported with carvedilol.</li></ul></li><li><strong>Insulin and oral antidiabetic drugs</strong> — prescribe with caution due to masking of symptoms of hypoglycaemia.</li><li><strong>Sympathomimetic agents</strong> — risk of hypertension, severe bradycardia, and heart block.</li><li><strong>Any other drugs that reduce blood pressure</strong> (including nitrates) — risk of additive hypotensive effect, or worsening of heart failure.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Baxter, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016j</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016k</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016l</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BNF 72, 2016</a>]</p><!-- end field 3d88d349-12cf-4017-a43e-d5076aa38935 --><!-- end item 7ca7aadd-5f19-4cda-b721-3444617b1368 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}